View on Pubmed.gov 40747931 | View on doi.org 10.1021/acs.jme...
Development of the First Small-Molecule Inhibitor Targeting Oncostatin M for Treatment of Breast Cancer.
- Department of Biomolecular Sciences, Boise State University, Boise, Idaho 83725, United States.
- Department of Biological Sciences, Boise State University, Boise, Idaho 83725, United States.
- Department of Chemistry and Biochemistry, Boise State University, Boise, Idaho 83725, United States.
- Biomedical Research Institute, Boise State University, Boise, Idaho 83725, United States.
- Biomedical and Pharmaceutical Sciences, Idaho State University, Meridian, Idaho 83642, United States.
Abstract
Oncostatin M (OSM) is a proinflammatory cytokine implicated in inflammatory diseases and multiple cancers, especially breast cancer. To date, no federally approved anti-OSM therapeutics exist. We computationally screened ∼1.65 million compounds to identify small-molecule inhibitors (SMIs) of the OSM, and candidates were validated in human breast cancer models. We identified a tetrasubstituted furan (SMI-10) that inhibited OSM signaling, and optimization generated SMI-10B (K D = 12.9 μM) and SMI-10B13 (K D = 6.6 μM). SMI-10B13 strongly inhibited OSM-mediated STAT3 phosphorylation in T47D and MCF-7 cell lines (IC 50= 136 and 164 nM, respectively). Fluorescence quenching, NMR, and surface plasmon resonance assays were used to characterize SMI/OSM interactions and identify a number of analogs with low-micromolar affinity for OSM. In a human breast cancer mouse model, SMI-10B13 reduced tumor growth (p < 0.001). Kaplan-Meier analysis showed improved survival in SMI-10B13-treated mice (p = 0.04), highlighting its potential as the first anti-OSM therapeutic to inhibit breast cancer progression and extend survival.
References
Biol Proced Online. 2012 Apr 17;14(1):6
Front Immunol. 2019 May 28;10:1164
Cancer Manag Res. 2018 Dec 05;10:6685-6693
Prog Nucl Magn Reson Spectrosc. 2013 Aug;73:1-16
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •